Lu Renrui, Zhang Li, Wang Huihui, Li Meng, Feng Weisheng, Zheng Xiaoke
School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Zhengzhou, China.
Front Pharmacol. 2023 Jan 4;13:993483. doi: 10.3389/fphar.2022.993483. eCollection 2022.
The present study was performed to investigate the antidepressant effect of echinacoside (ECH) using chronic unpredictable mild stress (CUMS) induced depression mice and lipopolysaccharide (LPS)-stimulated N9 microglial cells. CUMS treatment was performed on C57BL/6 mice for 28 days, followed by gavaging with different doses of echinacoside (15 and 60 mg/kg) for 21 consecutive days. Sucrose preference test (SPT), open field test (OFT), tail suspension test (TST), and forced swimming test (FST) were measured to assess the effects of echinacoside on CUMS-Induced Depressive-Like Behaviors. After that, the pathological changes of hippocampus were determined by Hematoxylin and eosin (HE) staining and Nissl staining; the neurotransmitters, pro-inflammatory cytokines and indoleamine 2,3-dioxygenase (IDO) levels, and the hypothalamic-pituitary-adrenal (HPA) axis activity were determined by enzyme linked immunosorbent assay (ELISA); Iba 1were evaluated by Immunofluorescence assay; Key protein expression levels of CREB/BDNF signal pathway were measured by western blotting. Subsequently, N9 cells were stimulated with 1 μg/ml LPS to induce N9 microglia activation, and were treated with 5-20 μM of echinacoside for 24 h. After that, the levels of NO, interleukin (IL)-1β, IL-6, tumor necrosis factor alpha (TNF-α), IL-4, IL-10, and transforming growth factor beta (TGF-β) in N9 cell culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA) kits; morphology and Iba 1 expression level were observed by high-content screening assay; the M1 markers of CD11b, CD86 and M2 markers of CD206 were analyzed by imaging flow cytometry. Results show that treatment with echinacoside reversed CUMS-increased immobility time in OFT, TST, FST and reversed CUMS-reduced sucrose preference in SPT. In addition, echinacoside reduced the levels of pro-inflammatory cytokines and Iba 1. Moreover, echinacoside significantly increased p-CREB/CREB ratio and BDNF level in hippocampus. Furthermore, echinacoside reduced the secretion of inflammatory factors and inhibited microglia M1 polarization in N9 cells. In conclusion, echinacoside may be beneficial for the treatment of depression diseases through regulating the microglia balance by inhibiting the polarization of microglia to M1 phenotype, and improving hippocampal neurogenesis by the CREB-BDNF signaling pathway.
本研究旨在利用慢性不可预测温和应激(CUMS)诱导的抑郁小鼠和脂多糖(LPS)刺激的N9小胶质细胞,研究紫锥菊苷(ECH)的抗抑郁作用。对C57BL/6小鼠进行28天的CUMS处理,随后连续21天灌胃不同剂量的紫锥菊苷(15和60mg/kg)。通过蔗糖偏好试验(SPT)、旷场试验(OFT)、悬尾试验(TST)和强迫游泳试验(FST)来评估紫锥菊苷对CUMS诱导的抑郁样行为的影响。之后,通过苏木精和伊红(HE)染色及尼氏染色确定海马的病理变化;通过酶联免疫吸附测定(ELISA)测定神经递质、促炎细胞因子和吲哚胺2,3-双加氧酶(IDO)水平以及下丘脑-垂体-肾上腺(HPA)轴活性;通过免疫荧光测定评估离子钙接头蛋白1(Iba 1);通过蛋白质免疫印迹法测定CREB/BDNF信号通路的关键蛋白表达水平。随后,用1μg/ml LPS刺激N9细胞以诱导N9小胶质细胞活化,并用5-20μM的紫锥菊苷处理24小时。之后,通过酶联免疫吸附测定(ELISA)试剂盒测定N9细胞培养上清液中一氧化氮(NO)、白细胞介素(IL)-1β、IL-6、肿瘤坏死因子α(TNF-α)、IL-4、IL-10和转化生长因子β(TGF-β)的水平;通过高内涵筛选测定观察形态和Iba 1表达水平;通过成像流式细胞术分析CD11b的M1标志物、CD86和CD206的M2标志物。结果表明,紫锥菊苷治疗可逆转CUMS增加的OFT、TST、FST中的不动时间,并逆转CUMS降低的SPT中的蔗糖偏好。此外,紫锥菊苷降低了促炎细胞因子和Iba 1的水平。此外,紫锥菊苷显著提高了海马中磷酸化CREB/CREB比值和脑源性神经营养因子(BDNF)水平。此外,紫锥菊苷减少了炎症因子的分泌,并抑制了N9细胞中小胶质细胞的M1极化。总之,紫锥菊苷可能通过抑制小胶质细胞向M1表型极化来调节小胶质细胞平衡,并通过CREB-BDNF信号通路改善海马神经发生,从而对抑郁症的治疗有益。